AI: Effect of Artıfıcıal Intellıgence Based Mobıle Vırtual Assıstant

Sponsor
Izmir Tinaztepe University (Other)
Overall Status
Completed
CT.gov ID
NCT06079450
Collaborator
(none)
1
1
13.9
0.1

Study Details

Study Description

Brief Summary

Aim: This study was conducted experimentally to examine the effect of artificial intelligence-based mobile virtual assistant developed for individuals with diabetes on cost, hospitalization rate, self-care and hypoglycemia.

Methods: The research is multi-stage and designed as three stages in itself. According to this; development of the mobile application in the first and second stages and adding artificial intelligence to the application as a project; In the third stage, it was planned to examine the effect of the application on the variables and scales. The data of the study were collected between June 2022 and June 2023 in the Endocrinology Polyclinic of two private hospitals in Izmir and a diabetes association where individuals with diabetes were registered. Power 0.80 was determined by using NCSS PAS statistical software from the population of the research; The minimum number of samples to be included in the study was calculated as n:122 and they were divided into two as intervention and control groups by randomization. The research sample was carried out as intervention (n:60) and control (n:60) lastly due to death and cost. Five data collection tools were used, namely "Individual Introduction Form", "Diabetes Self-Care Scale", "Hypoglycemia Confidence Scale", "Mobile Application Opinion Form" and "Cost Table". An artificial intelligence-based mobile virtual assistant application was applied to the individuals with diabetes in the intervention group, and the data were collected three times, at the 0th, 6th and 12th months, and the costs were recorded. The standard outpatient trainings, which are currently applied, continued to be given to individuals with diabetes in the control group, the data were collected twice, at the beginning (0. month) and 12. months, and the costs were recorded. In the evaluation of the data, number, percentage, arithmetic mean, standard deviation, minimum and maximum median were calculated. Among the variables, chi-square, Kruskal Wallis, Mann Whitney U test and t test were used.

Condition or Disease Intervention/Treatment Phase
  • Other: artificial intelligence based mobile application

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
1 participants
Observational Model:
Other
Time Perspective:
Other
Official Title:
Effect of Artıfıcıal Intellıgence Based Mobıle Vırtual Assıstant Developed For Indıvıduals Wıth Dıabetes On Cost Effıcıency, Hospıtal Admıssıon Rate, Self-Care And Hypoglycemıa
Actual Study Start Date :
Jun 10, 2022
Actual Primary Completion Date :
Jan 10, 2023
Actual Study Completion Date :
Aug 7, 2023

Arms and Interventions

Arm Intervention/Treatment
experimental group

Artificial intelligence-based mobile application initiative was implemented for diabetes patients

Other: artificial intelligence based mobile application
Artificial intelligence-based mobile application developed by me that includes diabetes education for individuals with diabetes.

control group

no intervention was applied

Outcome Measures

Primary Outcome Measures

  1. Diabetes Self-Care Scale [12 months]

    The score consists of 35 items and is a 4-point Likert type, the lowest acceptable score is 92 and the highest score is 140. As the score increases, self-care increases

  2. Hypoglycemic Confidence Scale [12 months]

    The scale consists of 9 items and is a 4-point Likert type. There is no cut-off value, the average score is used.

Secondary Outcome Measures

  1. hospitalization rate [12 months]

    percentage

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Having been diagnosed with Type 1 and Type 2 diabetes at least six months ago, according to the criteria of the American Diabetes Association (ADA),

  • Using insulin for at least six months,

  • Being between the ages of 18- 65,

  • Being able to read and write and speak Turkish,

  • Having an Android phone and being able to use mobile applications,

  • To volunteer to participate in the study.

Exclusion Criteria:

Contacts and Locations

Locations

Site City State Country Postal Code
1 Izmir Katip Celebi University Izmır Turkey 35620

Sponsors and Collaborators

  • Izmir Tinaztepe University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gökşen POLAT, Lecturer of Internal Medicine Nursing, Izmir Tinaztepe University
ClinicalTrials.gov Identifier:
NCT06079450
Other Study ID Numbers:
  • IKCU
First Posted:
Oct 12, 2023
Last Update Posted:
Oct 12, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Gökşen POLAT, Lecturer of Internal Medicine Nursing, Izmir Tinaztepe University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 12, 2023